Internal Medicine Alert
RSSArticles
-
Clinical Briefs
In this section: treating obstructive sleep apnea; influenza and myocardial infarction; and a promising Zika treatment.
-
Tildrakizumab-asmn Injection (Ilumya)
Tildrakizumab-asmn is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
-
Pre-existing Health Determines Quality of Life, Physical Symptoms After ICU Discharge
The authors of this nested cohort study within a randomized, controlled trial of ICU survivors requiring > 48 hours of mechanical ventilation found that pre-existing comorbidity was the main determinant of long-term health-related quality of life.
-
Hospital Ice Machines Contaminated With Bacteria
Requiring staff to cleanse their hands with alcohol hand gel prior to using an ice machine and directing housekeeping personnel to perform more frequent machine cleaning may improve situation.
-
Mefloquine: Still Effective and Still Safe for Malaria Chemoprophylaxis
Mefloquine is known as an effective agent for malaria chemoprophylaxis. However, concerns about serious adverse effects have limited its use. Now, a careful review of data suggests that fatal outcomes related to mefloquine prophylaxis are very rare.
-
What Form of AV Block?
The long lead II rhythm strip shown in the figure was obtained from a hemodynamically stable patient. The rhythm was diagnosed as showing second-degree AV block, Mobitz Type II. Do you agree with that assessment?
-
Clinical Briefs
In this section: comparing GLP-1 agonists; weighing two treatments for extended venous thromboembolism; and considering fracture risks possibly associated with inhaled corticosteroids.
-
Ibalizumab-uiyk Injection (Trogarzo)
Ibalizumab-uiyk, in combination with other antiretrovirals, is indicated for the treatment of HIV-1 in heavily treatment-experienced adults with multidrug-resistant HIV infections failing their current regimens.
-
After Myocardial Infarction, Increased Risk for Ischemic Stroke Persists for 12 Weeks
This study establishes that the elevated short-term risk of stroke extends beyond 30 days and remains elevated for up to 12 weeks following acute myocardial infarction.
-
Stroke Risk in Atrial Fibrillation: A Moving Target?
An investigation of patients in a national database with atrial fibrillation, no comorbidities, and not on aspirin or anticoagulants showed that the clinical features that make up the CHA2DS2-VASc score change over time and can increase a patient’s risk for stroke, which could affect therapy decisions. Thus, the CHA2DS2-VASc score should be reassessed periodically and appropriate therapeutic actions taken promptly.